
June 20, 2025 Freelancers, Licensing & business development, Research and Development Devices, Johnson & Johnson, Nanoform Finland, Oncology, amorphous solid dispersion technology, government loan, nanoparticle medicine, nanotechnology, prostate cancer
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

